Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE
Medicus Pharma (NASDAQ:MDCX) has submitted an Investigational New Drug application to Abu Dhabi's Department of Health for PRECISION-E2, a Phase 2a clinical trial evaluating its Teverelix drug candidate in women with symptomatic endometriosis in the United Arab Emirates. The study will enroll approximately 84 women across multiple sites in the UAE and test three different Teverelix dosing regimens, delivered by injection, to determine which dose and method best controls estrogen levels while minimizing side effects.
Medicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix
Medicus Pharma (NASDAQ:MDCX) has filed a substantial modification application through the European Union Clinical Trials Information System to advance a Phase 2b study of its prostate cancer treatment Teverelix, the company said on Monday. The planned trial will focus on patients with advanced prostate cancer and elevated cardiovascular risk who require androgen deprivation therapy (ADT), a segment the company estimates represents roughly $4 billion in annual market opportunity across major pharmaceutical markets.
Medicus Pharma advances SkinJect for Gorlin syndrome – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the filing of a registration study with the US Food and Drug Administration (FDA) for its SkinJect program targeting patients with Gorlin syndrome, marking a potentially important step toward commercialization of the technology. Speaking with Proactive, chief executive Raza Bokhari said the company has continued to advance SkinJect, a non-invasive treatment platform designed for non-melanoma skin diseases, particularly basal cell carcinoma.
Medicus Pharma Ltd Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 May Hill Capital LLC May Hill Capital LLC | 35,622 | $80,506 | $12,111.48 | -$68,394.52 | -84.96% |
Medicus Pharma Ltd Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JK Jason Kolbert D. Boral Capital | 22,051.79 | $6,615.06 | $7,497.61 | $882.55 | 13.34% |
Medicus Pharma Ltd (MDCX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Medicus Pharma Ltd ever had a stock split?
Medicus Pharma Ltd Profile
| Biotechnology Industry | Healthcare Sector | Raza Bokhari CEO | NASDAQ (CM) Exchange | 58471K202 CUSIP |
| CA Country | 12 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Medicus Pharma Ltd stands out as a leading entity in the pharmaceutical industry, concentrated on the research, development, and bringing to market innovative health care solutions. The core mission of the firm is to cater to unmet medical needs through the creation of a diversified portfolio of therapeutic treatments, concentrating primarily on areas such as oncology, neurology, and immunology. With a heavy reliance on biotechnology and avant-garde medical research, Medicus Pharma Ltd is firmly positioned as a significant figure in the life sciences domain. The organization is deeply committed to enhancing the quality and efficacy of treatments, thereby contributing significantly to the elevation of global healthcare standards. Beyond its influence on the pharmaceutical landscape, Medicus Pharma Ltd is instrumental in enhancing the health and well-being of patients and healthcare systems worldwide. As a frontrunner in the market, it engages in collaborations with academic bodies and industry counterparts, aiming to stimulate innovation and hasten the delivery of potentially life-saving drugs.
Products and Services
The range of products and services offered by Medicus Pharma Ltd is extensive, with each category tailored to address specific healthcare challenges:
- Oncology Treatments: Medicus Pharma Ltd develops innovative therapies aimed at treating various forms of cancer. These treatments focus on improving patient outcomes and include targeted therapy, immunotherapy, and traditional chemotherapy. By leveraging the latest research in oncology, the company strives to offer more effective and less toxic options to patients.
- Neurology Solutions: In the realm of neurology, the company is dedicated to discovering treatments for neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Through cutting-edge research, Medicus Pharma Ltd aims to provide patients with treatments that can alleviate symptoms, halt disease progression, and improve quality of life.
- Immunology Therapies: Focusing on disorders of the immune system such as autoimmune diseases, Medicus Pharma Ltd is at the forefront of developing therapies that modulate the immune response. These treatments are designed to target underlying causes of immune-related conditions, offering new hope to patients suffering from diseases like rheumatoid arthritis, lupus, and inflammatory bowel disease.
Each product and service provided by Medicus Pharma Ltd encapsulates the company's commitment to pioneering healthcare advancements, ensuring that their offerings not only meet the highest standards of safety and effectiveness but also address the evolving needs of patients and healthcare professionals around the globe.
